Please login to the form below
CEPI
This page shows the latest CEPI news and features for those working in and with pharma, biotech and healthcare.
China’s Sinopharm given WHO emergency use listing for COVID-19 vaccine
COVAX is the vaccine pillar of the WHO’s ACT Accelerator – a collaborative initiative co-led by Gavi, the WHO and the Coalition for Epidemic Preparedness Innovations (CEPI) that is working
Latest news
-
WHO to review Moderna’s COVID-19 vaccine for emergency use listing this week
COVAX is the vaccine pillar of the WHO’s ACT Accelerator – a collaborative initiative co-led by Gavi, the WHO and the Coalition for Epidemic Preparedness Innovations (CEPI) that is working
-
WHO backs emergency use of J&J’s one-dose COVID-19 vaccine
COVAX is the vaccine pillar of the WHO’s ACT Accelerator – a collaborative initiative co-led by Gavi, the WHO and the Coalition for Epidemic Preparedness Innovations (CEPI) that is aiming
-
Stakeholder meeting kick-starts dialogue on COVID-19 vaccine supply chain issues
need to deliver them,” said Richard Hatchett, chief executive officer of CEPI.
-
First shipments of AZ/Oxford COVID-19 vaccine sent through COVAX
countries. In June 2020, AZ signed agreements with the Coalition for Epidemic Preparedness Innovation (CEPI), Gavi the Vaccine Alliance and SII. ... This included a $750m agreement with CEPI and Gavi to support the manufacturing, procurement and
-
J&J submits one-dose COVID-19 vaccine to WHO for emergency use listing
COVAX is the vaccine pillar of the WHO’s ACT Accelerator – a collaborative initiative co-led by Gavi, the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI)
WHO to review Moderna’s COVID-19 vaccine for emergency use listing this week
Stakeholder meeting kick-starts dialogue on COVID-19 vaccine supply chain issues
First shipments of AZ/Oxford COVID-19 vaccine sent through COVAX
J&J submits one-dose COVID-19 vaccine to WHO for emergency use listing
More from news
Approximately 3 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Developing a COVID-19 vaccine
In March the CEPI called for new funding for the expansion of potential vaccine candidates, saying that $2bn is needed to support the development of a successful COVID-19 vaccine. ... stockpiled and ready for trials and emergency authorisation should an
Developing a COVID-19 vaccine
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
What does the COVID-19 vaccine mean for the future of R&D?
The Coalition for Epidemic Preparedness Innovation (CEPI), for example, has been supporting the development of vaccines against five emerging pathogens on the World Health Organization priority list, since its genesis in ... 2017. CEPI also supports the
-
Is the world ready for a COVID-19 vaccine?
One of the ways the world is looking to mitigate this is through the COVAX initiative, which is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), the Global Alliance
-
Understanding COVID-19 and varying responses across the globe
The Coalition for Epidemic Preparedness Innovation (CEPI), a global alliance financing and coordinating the development of vaccines against emerging infectious diseases, launched in 2017 and is needed now more than ever.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
CEO, Head of Health, UK
-
Six figure salary
-
CEO Pricing & Market Access, UK
-
Six figure salary
-
Senior Account Manager
-
Competitive salary offered
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
- US demand for COVID-19 antibody treatments rising fast
- Valneva COVID-19 vaccine more effective than AZ
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Call for industry innovators to join working group
- Pfizer-BioNTech booster offers 95.6% efficacy against COVID-19
- US COVID-19 booster programme expanded
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- Towards Better HCP Engagement – An Email Masterclass
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Beyond yoga and smoothies – providing real support for employee well-being
- The Future of eHealth: Contactless Health Monitoring
- Reckitt to spin-off pharma unit as Indivior
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
PMHub
Market Access Transformation
Founded in 201, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange...
Latest intelligence
- The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
- The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
- Mind the Gap – Challenging Immunisation Apathy and Misinformation
- world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
- Towards Better HCP Engagement – An Email Masterclass
- 6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....
